DBMR - Pharmaceutical

Global Hemophilia Treatment Market– Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Dec 2018
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Hemophilia Treatment Market, By Product (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents), Type (Hemophilia A, Hemophilia B, Hemophilia C, Others), Therapy (On-Demand, Prophylaxis), Treatment (Replacement Therapy, ITI Therapy, Gene Therapy), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends & Forecast to 2026

Market Analysis: Global Hemophilia Treatment Market 

Global Hemophilia Treatment Market is expected to rise from its initial estimated value of USD 18.69 billion in 2018 to an estimated value of USD 28.25 billion by 2026, registering a CAGR of 5.3% in the forecast period of 2019-2026. Increased diagnosis of the disease and rise of prophylactic treatment is expected to drive the market growth.

Market Definition: Global Hemophilia Treatment Market 

Hemophilia is a unique genetic bleeding disorder which is caused by the lack of clotting proteins present in the blood, which causes the patients suffering from it to bleed longer than usual if they suffer an injury or even bleed internally in ankles, elbows and knees. The different types of hemophilia are associated with the lack of different type of clotting factors associated with it.

Market Drivers:

  • Increased amount of patient diagnosed with hemophilia is expected to drive the market growth
  • Rising use of prophylactic treatments in hemophilia patients is also expected to act as a driver for the market growth

Market Restraints:

  • High cost and stringent regulations posed by the authorities is expected to restrain the market growth
  • Adverse side effects of plasma treatment products is also expected to restrain the market growth

Segmentation: Global Hemophilia Treatment Market 

  • By Product

    • Plasma-Derived Coagulation Factor Concentrates

      • Factor VIII
      • Factor IX
      • Factor XIII
      • Activated Prothrombin Complex Concentrate
      • Von Willebrand Factor

    • Recombinant Coagulation Factor Concentrates

      • Factor VIII
      • Factor IX
      • Von Willebrand Factor

    • Desmopressin
    • Antifibrinolytic Agents

  • By Type

    • Hemophilia A
    • Hemophilia B
    • Hemophilia C
    • Others

  • By Therapy

    • On-Demand
    • Prophylaxis

  • By Treatment

    • Replacement Therapy
    • Immune Tolerance Induction Therapy
    • Gene Therapy

  • By Geography

    • North America

      • US
      • Canada
      • Mexico

    • South America

      • Brazil
      • Argentina
      • Rest of South America

    • Europe

      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe

    • Asia-Pacific

      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific

    • Middle East and Africa

      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Key Developments in the Market:

  • In April 2016, BioMarin announced preliminary data from phase I/II trial results for BMN 270, an investigational gene therapy treatment for hemophilia A.
  • In June 2016, Shire announced that they had completed the acquisition of Baxalta, expanding their market share and emphasizing their superiority

Competitive Analysis: Global Hemophilia Treatment Market 

The global hemophilia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hemophilia treatment market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Hemophilia Treatment Market 

Few of the major competitors currently working in the hemophilia treatment market are Baxter, Grifols S.A., CSL Limited, Octapharma, Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Biogen, Shire, F. Hoffmann-La Roche Ltd, Ferring B.V., Sanofi, Swedish Orphan Biovitrum AB (publ), BioMarin, and Sangamo Therapeutics.

Research Methodology: Global Hemophilia Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global hemophilia treatment market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART